Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Net Cash Flow (2018 - 2025)

Serina Therapeutics (SER) has disclosed Net Cash Flow for 8 consecutive years, with -$5.6 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 1380.78% to -$5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$647000.0 through Dec 2025, up 83.61% year-over-year, with the annual reading at -$647000.0 for FY2025, 83.61% up from the prior year.
  • Net Cash Flow hit -$5.6 million in Q4 2025 for Serina Therapeutics, down from $2.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $8.8 million in Q2 2023 to a low of -$5.6 million in Q4 2025.
  • Historically, Net Cash Flow has averaged $150050.0 across 5 years, with a median of $141000.0 in 2021.
  • Biggest five-year swings in Net Cash Flow: surged 3368.5% in 2023 and later plummeted 1380.78% in 2025.
  • Year by year, Net Cash Flow stood at $103000.0 in 2021, then soared by 73.79% to $179000.0 in 2022, then plummeted by 78.77% to $38000.0 in 2023, then surged by 1050.0% to $437000.0 in 2024, then tumbled by 1380.78% to -$5.6 million in 2025.
  • Business Quant data shows Net Cash Flow for SER at -$5.6 million in Q4 2025, $2.6 million in Q3 2025, and $1.7 million in Q2 2025.